Aveanna Healthcare's Home Health and Hospice division received CHAP Disease Program Certification for Heart Failure, demonstrating compliance with industry's highest standards. The certification recognizes Aveanna's Heartways program, a scientifically validated care initiative that improves outcomes for heart disease patients through comprehensive education, symptom monitoring, and palliative care protocols.

Patrick Cunningham, chief compliance officer of Aveanna Healthcare, sold 36,015 shares worth $292,488 between December 30 and January 2. The sale represented 10.93% of his direct holdings but was driven by tax obligations from vested equity awards rather than discretionary selling. Despite the insider sale, the company is experiencing strong operational momentum with Q3 revenue up 22.2% and adjusted EBITDA surging 67.5%, with shares up 99% over the past year.

Aveanna Healthcare Holdings will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026, offering a presentation and investor meetings.

Aveanna Healthcare Holdings will virtually attend the BofA Securities Home Care Conference on December 9, 2025, presenting at 12:30pm EST and hosting investor meetings.

Aveanna Healthcare Holdings is conducting a secondary offering of 10 million shares at $9.00 per share, with selling stockholders receiving all net proceeds. The offering is managed by multiple investment banks and expected to settle on October 23, 2025.

Aveanna Healthcare Holdings Inc. announced its management team will attend the Deutsche Bank Annual Leveraged Finance Conference in Austin, TX on October 15, 2025, and host investor meetings.

Aveanna Healthcare Holdings Inc. has completed the acquisition of Thrive Skilled Pediatric Care, LLC, a leading provider of pediatric home care services. The combination creates an enhanced footprint for Aveanna and expands its specialized care model.

Aveanna Healthcare Holdings Inc. has entered into an agreement to acquire Thrive Skilled Pediatric Care, one of the largest independent providers of pediatric home care. The combination will enhance Aveanna's footprint in existing states and introduce its specialized care model into two new states.

Axonics received regulatory approval from the Therapeutic Goods Administration in Australia to market its R20 rechargeable sacral neuromodulation (SNM) system, which features a 20-year functional life and reduced recharge frequency. However, Axonics' shares fell despite this positive development.

Three healthcare stocks, Aveanna Healthcare Holdings Inc, Revolution Medicines, and Fulcrum Therapeutics, have seen significant price gains recently, indicating they may be overbought and could pose risks to investors focused on momentum trading.

ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the UBS Healthcare Services Cape Cod Summit in Chatham, MA on Tuesday, June 4, 2024, and the Jefferies Global Healthcare Conference in New York on Wednesday, June 5, 2024.

Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.